Re: Aesthetic-medicine shorts
>Why don't we move on to fillers. I like your ideas about possible shorts. The filler business now is a little like the medical electronic industry in the 70s. New products roll in to displace old ones. Overnight success and overnight failure.<
The two main fillers—Restylane and Juvederm—are sold by profitable companies (AGN and MRX) who have with broad product lines. Moreover, I think these two products will do well in the marketplace. Hence, there is no compelling short idea here. (I shorted AGN successfully in 2006, but that was based on valuation only.)
The best shorting opportunities in this arena are (IMO) the one-product companies where the one product is a loser. Thus, I’ve tagged THRM and ARTE for my shorting watchlist. Both are late 2006 IPOs, which means that insiders will likely unload some shares when the respective IPO lockups expire.
Market Data 
Markets 
AI
